Advanced search
Publication Cover
ClinicoEconomics and Outcomes Research Volume 3, 2011 - Issue
Submit an article Journal homepage
66
Views
18
CrossRef citations to date
0
Altmetric
Methodology

Cost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in Iran

Hamid Reza Rasekh1 Shahid Beheshti University of Medical Sciences, Department of Pharmaceutical Management and Pharmacoeconomics, School of Pharmacy, Tehran
,
Ali Imani1 Shahid Beheshti University of Medical Sciences, Department of Pharmaceutical Management and Pharmacoeconomics, School of Pharmacy, TehranCorrespondence[email protected]
,
Mehran Karimi2 University of Shiraz Medical Sciences, Hematology Research Center, Shiraz, Iran
&
Mina Golestani1 Shahid Beheshti University of Medical Sciences, Department of Pharmaceutical Management and Pharmacoeconomics, School of Pharmacy, Tehran
Pages 207-212 | Published online: 23 Nov 2011

Citations (18)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

E. Carlos Rodriguez-Merchan. (2020) The cost of hemophilia treatment: the importance of minimizing it without detriment to its quality. Expert Review of Hematology 13:3, pages 269-274.
Read now
Saeed Taheri, Mohammad Ali Sahraian & Nazila Yousefi. (2019) Cost-effectiveness of alemtuzumab and natalizumab for relapsing-remitting multiple sclerosis treatment in Iran: decision analysis based on an indirect comparison. Journal of Medical Economics 22:1, pages 71-84.
Read now
Akbar Dorgalaleh, Ghazaleh Dadashizadeh & Taregh Bamedi. (2016) Hemophilia in Iran. Hematology 21:5, pages 300-310.
Read now

Articles from other publishers (15)

Mouaddh Abdulmalik Nagi, Pramitha Esha Nirmala Dewi, Montarat Thavorncharoensap & Sermsiri Sangroongruangsri. (2021) A Systematic Review on Economic Evaluation Studies of Diagnostic and Therapeutic Interventions in the Middle East and North Africa. Applied Health Economics and Health Policy 20:3, pages 315-335.
Crossref
Reza Hashempour, Behzad Raei, Majid Safaei Lari, Nasrin Abolhasanbeigi Gallezan & Ali AkbariSari. (2021) QALY league table of Iran: a practical method for better resource allocation. Cost Effectiveness and Resource Allocation 19:1.
Crossref
Parisa Saiyarsarai, Atefeh Robabpour Derakhshan, Jamaleddin Khedmati, Peyman Eshghi & Meysam Seyedifar. (2021) A comparison between on-demand usage of rFVIIa vs prophylaxis use of emicizumab in high titer inhibitory hemophilia A patients in Iran. Medicine 100:40, pages e27303.
Crossref
Farhad Lotfi, Hamid Talebianpour, Khosro Keshavarz, Fatemeh Emadi, Mohammad Reza Bordbar & Peivand Bastani. (2020) Cost-utility analysis of factor VIII diet therapies prepared using blood plasma vs. recombinant technique for patients with hemophilia A. DARU Journal of Pharmaceutical Sciences 28:1, pages 287-293.
Crossref
Charles Nakar & Amy Shapiro. (2019) Hemophilia A with inhibitor: Immune tolerance induction (ITI) in the mirror of time. Transfusion and Apheresis Science 58:5, pages 578-589.
Crossref
Lucia S. D'Angiolella, Paolo A. Cortesi, Angiola Rocino, Antonio Coppola, Hamisa J. Hassan, Adele Giampaolo, Luigi P. Solimeno, Alessandra Lafranconi, Mariangela Micale, Sveva Mangano, Giacomo Crotti, Federica Pagliarin, Giancarlo Cesana & Lorenzo G. Mantovani. (2018) The socioeconomic burden of patients affected by hemophilia with inhibitors. European Journal of Haematology 101:4, pages 435-456.
Crossref
Teja ThoratPeter J. NeumannJames D. Chambers. (2018) Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for Hemophilia. Journal of Managed Care & Specialty Pharmacy 24:7, pages 632-642.
Crossref
Paolo A. Cortesi, Lucia S. D’Angiolella, Alessandra Lafranconi, Mariangela Micale, Giancarlo Cesana & Lorenzo G. Mantovani. (2017) Modern Treatments of Haemophilia: Review of Cost-Effectiveness Analyses and Future Directions. PharmacoEconomics 36:3, pages 263-284.
Crossref
M. Drummond, N. Houwing, U. Slothuus & P. Giangrande. (2017) Making economic evaluations more helpful for treatment choices in haemophilia. Haemophilia 23:2, pages e58-e66.
Crossref
Maria Elisa Mancuso & Antonino Cannavò. (2015) Immune tolerance induction in hemophilia. Clinical Investigation 5:3, pages 321-335.
Crossref
Mina Golestani, Peyman Eshghi, Hamid Reza Rasekh, Abdol Majid Cheraghali, Jamshid Salamzadeh & Ali Imani. (2014) Bypassing Agents for Bleeding Reduction in Treatment of Bleeding Episodes in Patients With Haemophilia and Inhibitors. Iranian Red Crescent Medical Journal 16:12.
Crossref
A. R. Kachooei, Z. Badiei, M. E. Zandinezhad, M. H. Ebrahimzadeh, S. M. Mazloumi, F. Omidi-Kashani, A. Moradi, R. Mahdavian-Naghashzargar & S. Razi. (2014) Influencing factors on the functional level of haemophilic patients assessed by FISH. Haemophilia 20:2, pages 185-189.
Crossref
Carmen de Cos & Javier Rodríguez-Martorell. (2014) Successful immune tolerance induction with a plasma-derived FVIII concentrate and intravenous immunoglobulins in a pediatric patient with congenital severe hemophilia A and poor prognostic factors. Blood Coagulation & Fibrinolysis 25:1, pages 77-80.
Crossref
E. Carlos Rodriguez-Merchan. (2012) Differing approaches to diagnosis and treatment of musculoskeletal complications of haemophilia in resource-rich and resource-limited settings. Blood Coagulation & Fibrinolysis 23:7, pages 575-579.
Crossref
Abdol Majid Cheraghali & Peyman Eshghi. (2012) Cost Assessment of Implementation of Immune Tolerance Induction in Iran. Value in Health Regional Issues 1:1, pages 54-58.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.